Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CLRB Hot Sheet
Join SI Premium – FREE
Cellectar Biosciences (NASDAQ: CLRB) reported Q2 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Cellectar Biosciences (CLRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Contineum Therapeutics (CTNM) PT Lowered to $23 at Stifel
- Caterpillar shares fall amid analyst downgrades
- Rapport Therapeutics (RAPP) PT Lowered to $73 at Raymond James
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
